

RUO Bispecific Antibodies for Translational Discovery

Ready-to-Ship and Custom Bispecific Antibody Solutions from Bio X Cell

- Translationally aligned formats:** Ready-to-ship anti-mouse and anti-human bispecifics for research continuity
- RUO-grade quality:** $\geq 95\%$ purity, ≤ 0.5 EU/mg endotoxin, and carrier-free formulations for reproducible results
- Immediate access:** In-stock bispecifics enable faster study starts and reduced evaluation cycles.
- Custom capability:** Tailored designs with Fc and architecture options; delivered in as little as four weeks
- Scalable supply:** U.S.-based recombinant production ensures consistent quality to meet mg to g-scale needs

Featured Anti-Mouse Bispecific Antibody	SKU	Description	Details
<u>Bispecific mouse IgG2a (LALA-PG)-scFv, kappa isotype control</u>	<u>CPB500</u>	Isotype control HRPN X LTF2	2+2 symmetric tetravalent isotype control that reacts with proteins not expressed by mammals
<u>Bispecific anti-mouse PD-1 x anti-mouse VEGF-A (LALA-PG)</u>	<u>CPB501</u>	PD-1 (RMP1-14) x VEGF-A (2G11-2A05)	2+2 symmetric tetravalent that targets PD-1 and VEGF-A to inhibit tumor immune evasion
<u>Bispecific anti-mouse CD3 x anti-mouse CD20 (LALA-PG)</u>	<u>CPB502</u>	CD3 (145-2C11) x CD20 (MB20-11)	1+1 symmetric bivalent CD20-directed CD3 engager that activates and recruits cytotoxic T cells to kill CD20 ⁺ cells
<u>Bispecific mouse IgG2a (LALA-PG), kappa isotype control</u>	<u>CPB503</u>	Isotype control HRPN x LTF2	1+1 symmetric bivalent isotype control that reacts with proteins not expressed by mammals
<u>Bispecific anti-mouse PD-1 x anti-mouse CTLA-4</u>	<u>CPB504</u>	PD-1 (RMP1-14) x CTLA-4 (9D9)	1+1 tetravalent that targets PD-1 and CTLA-4 to deliver dual checkpoint blockade, restoring T cell activity and boosting CD28 stimulation



Scan to View All
Ready-to-Ship and
Custom Bispecific
Antibody Options

Bispecific Options
Built for Modern
Preclinical Workflows

Featured Ready-to-Ship Anti-Mouse Bispecific Antibodies

Product Name	SKU	Description	Details
<u>Bispecific anti-mouse PD-1 x anti-mouse CTLA-4</u>	<u>CPB505</u>	PD-1 (RMP1-14) x CTLA-4 (9D9)	2+2 tetravalent that targets PD-1 and CTLA-4 to deliver dual checkpoint blockade, restoring T cell activity and boosting CD28 stimulation
<u>Bispecific anti-mouse LAG3 x anti-mouse CTLA-4</u>	<u>CPB506</u>	LAG3 (C9B7W) x CTLA-4 (9D9)	1+1 bivalent that targets LAG3 and CTLA-4 to block two inhibitory receptors to reinvigorate T cells and enhance anti-tumor T cell responses
<u>Bispecific mouse scFv IgG2a, kappa isotype control</u>	<u>CPB509</u>	Isotype control HRPN x LTF2	2+2 symmetric tetravalent isotype control that reacts with proteins not expressed by mammals
<u>Bispecific anti-mouse PD-1 x anti-mouse PD-L1 (LALA-PG)</u>	<u>CPB510</u>	PD-1 (RMP1-14) x PD-L1 (10F.9G2)	2+2 symmetric tetravalent that targets PD-1 and PD-L1 to block inhibitory PD-1/PD-L1 pathway, preventing immune suppression
<u>Bispecific anti-mouse PD-L1 x anti-mouse CTLA-4</u>	<u>CPB512</u>	PD-L1 (10F.9G2) x CTLA-4 (9D9)	2+2 symmetric tetravalent that targets PD-L1 and CTLA-4 to enhance anticancer immunity by blocking immune checkpoints
<u>Bispecific anti-mouse LAG3 x anti-mouse PD-L1</u>	<u>CPB513</u>	LAG3 (C9B7W) x PD-L1 (10F.9G2)	2+2 symmetric tetravalent synergistically targets LAG3 and PD-L1 to enhance activation of T cells, improving anti-tumor response
<u>Bispecific anti-mouse PD-L1 x anti-mouse VEGF</u>	<u>CPB514</u>	PD-L1 (10F.9G2) x VEGF (2G11-2A05)	2+2 symmetric tetravalent that targets PD-L1 and VEGF to localize anti-VEGF activity to PD-L1 tumor sites while enhancing T-cell activation
<u>Bispecific anti-mouse LAG3 x anti-mouse PD-1</u>	<u>CPB515</u>	LAG3 (C9B7W) x PD-1 (RMP-14)	1+1 symmetric bivalent that targets LAG3 and PD-1 to reactivate anti-tumor activity